Shanghai Pharmaceuticals Holding (601607.SH): Omeprazole Sodium Bicarbonate Dry Suspension (I) Approved for Production
Shanghai Pharmaceuticals (601607.SH) announced that recently, its subsidiary Shanghai Shyang Pharmaceutical Co., Ltd. (referred to as "Shyang Pharmaceutical") received the "Drug Registration Certificate" (Certificate No.: 2026S02750) issued by the National Medical Products Administration for the Omeprazole Sodium Bicarbonate Dry Suspension (I), and the drug has been approved for production.
Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Shanghai Shiyu Pharmaceutical Factory Co., Ltd. (referred to as "Shiyu") has recently received the "Drug Registration Certificate" (Certificate No.: 2026S02750) issued by the National Medical Products Administration for Omeprazole Sodium Bicarbonate Dry Suspension (I), and this drug has been approved for production.
Omeprazole Sodium Bicarbonate Dry Suspension (I) (each bag contains 20mg of omeprazole and 1680mg of sodium bicarbonate) is mainly used for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease.
Related Articles
VITASOY INT'L (00345) repurchased 22,000 shares for HK$141,700 on August 3.
Chaozhou Three-Circle (Group) (06951) announced on August 3 that it spent 19.314 million yuan to repurchase 172,700 shares of A-shares.
Anhui Anke Biotechnology (300009.SZ): The raw material drug Octreotide has obtained EU CEP certification.
VITASOY INT'L (00345) repurchased 22,000 shares for HK$141,700 on August 3.
Chaozhou Three-Circle (Group) (06951) announced on August 3 that it spent 19.314 million yuan to repurchase 172,700 shares of A-shares.
Anhui Anke Biotechnology (300009.SZ): The raw material drug Octreotide has obtained EU CEP certification.
RECOMMEND
